Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, …
Over the last 12 months, insiders at Monte Rosa Therapeutics, Inc. have bought $0 and sold $12.3M worth of Monte Rosa Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Monte Rosa Therapeutics, Inc. have bought $276.75M and sold $12.3M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,050,000 shares for transaction amount of $19.95M was made by Yang Rick (10 percent owner) on 2021‑06‑28.
2024-10-29 | Sale | 10 percent owner | 67,905 0.1081% | $9.16 | $621,801 | -5.34% | ||
2024-10-28 | Sale | 10 percent owner | 89,990 0.2667% | $9.66 | $869,240 | 0.00% | ||
2024-09-20 | Sale | 10 percent owner | 1.13M 1.8595% | $6.53 | $7.4M | -18.21% | ||
2024-09-13 | Sale | 10 percent owner | 9,269 0.0153% | $6.16 | $57,100 | -10.03% | ||
2024-09-12 | Sale | 10 percent owner | 16,047 0.0263% | $6.00 | $96,309 | -7.89% | ||
2024-09-11 | Sale | 10 percent owner | 541,897 0.833% | $6.00 | $3.25M | +1.01% | ||
2024-07-05 | Sale | Principal Accounting Officer | 1,610 0.0027% | $3.83 | $6,166 | 0.00% | ||
2024-06-03 | Sale | Principal Accounting Officer | 1,207 0.002% | $4.04 | $4,876 | +27.64% | ||
2021-06-28 | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | |||
2021-06-28 | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | |||
2021-06-28 | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | |||
2021-06-28 | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | |||
2021-06-28 | director | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | |||
2021-06-28 | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | |||
2021-06-28 | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | |||
2021-06-28 | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | |||
2021-06-28 | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | |||
2021-06-28 | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | |||
2021-06-28 | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | |||
2021-06-28 | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% |
Versant Venture Capital VI, L.P. | 10 percent owner | 1573453 2.5638% | $9.46 | 1 | 6 | <0.0001% |
MAKOWER JOSHUA | 10 percent owner | 7692298 12.5337% | $9.46 | 1 | 0 | <0.0001% |
SANDELL SCOTT D | 10 percent owner | 7692298 12.5337% | $9.46 | 1 | 0 | <0.0001% |
BASKETT FOREST | 10 percent owner | 7692298 12.5337% | $9.46 | 1 | 0 | <0.0001% |
Mathers Edward T | 10 percent owner | 7692298 12.5337% | $9.46 | 1 | 0 | <0.0001% |
Nea Management Company Llc | $54.23M | 12.64 | 7.69M | 0% | +$0 | 0.25 | |
Fidelity Investments | $37.65M | 8.78 | 5.34M | -3.55% | -$1.38M | <0.01 | |
T. Rowe Price | $35.93M | 8.38 | 5.1M | +3.15% | +$1.1M | <0.01 | |
Baker Bros Advisors LP | $34.66M | 8.08 | 4.92M | 0% | +$0 | 0.25 | |
Avoro Capital Advisors Llc | $31.97M | 7.45 | 4.54M | 0% | +$0 | 0.38 |